GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » Quality Rank

Revive Therapeutics (FRA:31R) Quality Rank


View and export this data going back to 2017. Start your Free Trial

What is Revive Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Revive Therapeutics Quality Rank Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.